- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT00163605
Performance and Safety of Bone Substitute MBCP-FS in Maxillary Sinus Lift Procedures
14. november 2007 opdateret af: Baxter Healthcare Corporation
A Prospective Clinical Study to Evaluate the Performance and Safety of the Bone Substitute MBCP-FS in Maxillary Sinus Lift Procedures
The purpose of this study is to evaluate the performance and to monitor the safety of the bone substitute Macroporous Biphasic Calcium Phosphate-Fibrin Sealant Vapor Heated Solvent/Detergent Treated 4 IU/ML Thrombin (MBCP-FS) in Sinus Lift Procedures .
This study will be conducted in two parts: part A evaluates safety and performance of MBCP-FS in bone regeneration i.e. the amount of new bone that is formed and its suitability for dental implant placement.
Part B is designed to evaluate long-term safety and performance of the product, i.e. whether the newly-formed bone is suitable to retain implants.
Studieoversigt
Status
Afsluttet
Betingelser
Undersøgelsestype
Interventionel
Tilmelding
86
Fase
- Fase 2
- Fase 3
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiesteder
-
-
-
Erfurt, Tyskland, 99089
- Klinik für Mund-, Kiefer- und Gesichtschirurgie des Helios-Klinikums Erfurt
-
Erlangen, Tyskland, 91054
- Klinik und Poliklinik für Mund-, Kiefer- und Gesichtschirurgie der Universität Erlangen-Nürnberg
-
Kiel, Tyskland, 24105
- Universitatsklinikum Schleswig Holstein, Campus Kiel
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
18 år og ældre (Voksen, Ældre voksen)
Tager imod sunde frivillige
Ingen
Køn, der er berettiget til at studere
Alle
Beskrivelse
Inclusion criteria:
- Written informed consent obtained from the subject prior to participation in the study
- At least 18 years of age
- Partially or totally edentulous with an atrophic posterior maxilla requiring unilateral or bilateral sinus lift before dental implant placement
- In case of bilateral sinus lifts, both sides are operated on the same day.
- Subjects with remaining minimal maxillary bone height between 2 mm and 5 mm at the site with minimal height in the area where implants are planned, and a remaining maxillary bone thickness >= 5 mm in the area where implants are planned
Exclusion Criteria:
- Previous or coeval major surgical intervention in the targeted area, or major surgical intervention in the targeted area planned within the next 18 months (like Caldwell Luc) (minor interventions like surgical tooth extraction or root tip resections are allowed)
- Surgical tooth extraction in the targeted area less than three months before the SLP
- Maxillary and sinus disorders including: acute sinusitis, chronic sinus pathology, retained root tips, polyps, tumors, and cysts in antral cavity or odontogenic cysts, alveolar scar ablation
- Major occlusal disturbance, like severe bruxism
- Uncontrolled* periodontal disease
- An inadequate interarch distance requiring an oppositional graft
- Immune system disorders, immunodeficiency or immunosuppression
- Known coagulation disorder
- Uncontrolled* diabetes mellitus
- Severe hyperparathyroidism
- Receiving long-term anti-inflammatory treatment with NSAIDs or corticosteroids
- Chemotherapy current or in the last three months
- Having undergone maxillary radiation therapy
- Known hypersensitivity to aprotinin or to other components of the investigational product
- Abuse of alcohol or drugs or tobacco consumption of more than 5 cigarettes per day at study start
- Non-compliant for future dental hygiene
- Severely compromised physical and psychological health, that in the investigators opinion will affect patient compliance
- Any contra-indications to the use of MBCP, which are defined as osteomyelitis, degenerative bone disease or necrosis of the recipient site
- Concurrently participating in another clinical trial and having received another investigational drug or device within the last 30 days
Pregnant or lactating, or intending to become pregnant during the study period
- Uncontrolled = not treated or not stabilized after treatment
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Tildeling: Ikke-randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart
1. september 2004
Studieafslutning (Faktiske)
1. november 2007
Datoer for studieregistrering
Først indsendt
8. september 2005
Først indsendt, der opfyldte QC-kriterier
13. september 2005
Først opslået (Skøn)
14. september 2005
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
15. november 2007
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
14. november 2007
Sidst verificeret
1. november 2007
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 570201
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .